Luvometinib with or without chemotherapy for LCH
Treatments studied
Part of Blood & lymphatic, Lungs & breathing clinical trials.
This trial tests a new targeted drug called luvometinib, either alone or with a standard chemotherapy drug (cytarabine), for people with Langerhans cell histiocytosis. The goal is to see if adjusting the treatment based on your response can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of Langerhans cell histiocytosis (LCH) from a tissue sample.
- You are 10 years old or older.
- You need treatment for your LCH, and you have at least one tumor that can be seen on a PET scan.
- You are expected to live at least 12 more weeks, and you are able to follow the study plan.
- You are in good enough health to walk around and take care of yourself (ECOG 0-2 or Lansky score 60 or higher).
- Your organs like kidneys, liver, and heart must work well enough (checked by tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests a treatment plan that includes cytarabine for children newly diagnosed with LCH (a rare condition where abnormal immune-related cells form lesions). It may help control the disease while comparing outcomes with a cytarabine-based protocol.
This trial tests a targeted drug called trametinib (a MEK inhibitor) for people with Langerhans cell histiocytosis (LCH) that is newly diagnosed, relapsed, or hasn't responded to other treatments. It aims to see if trametinib can better control the disease with fewer side effects.
This trial tests a combination of two drugs, low-dose cytarabine and thalidomide, for adults with Langerhans cell histiocytosis (LCH) that has not been treated before with systemic therapy. The goal is to see if this treatment is safe and effective for people with LCH in multiple body areas or multiple spots in one system.
This trial tests a study drug, FCN-159, for children with a rare blood/immune disease called Langerhans cell histiocytosis (LCH) that has not responded to standard treatment or has come back. The goal is to see if this drug can shrink the LCH lesions and help the child feel better.
This Phase 2 trial studies cobimetinib, a medicine that targets a specific growth-and-signal pathway, to treat stubborn (refractory or worsening) Langerhans cell histiocytosis and related disorders. It may help shrink active disease or stop disease from progressing.
This phase 3 study compares two treatment plans for Langerhans cell histiocytosis (LCH): vinblastine plus prednisone versus cytarabine alone. It aims to find which approach works better and is safer for children and young adults with LCH that needs medicines.
Hear when a new Langerhans Cell Histiocytosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.